Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022010049 - COMPOSITION FOR CARDIOMYOCYTE TOXICITY ASSAY OF CANDIDATE DRUG FOR SARS-COV-2 VIRUS, USING HUMAN PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES, AND CARDIOMYOCYTE TOXICITY ASSAY METHOD USING SAME

Publication Number WO/2022/010049
Publication Date 13.01.2022
International Application No. PCT/KR2020/016771
International Filing Date 25.11.2020
IPC
G01N 33/50 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
Applicants
  • 주식회사 티앤알바이오팹 T&R BIOFAB CO., LTD. [KR]/[KR]
Inventors
  • 문성환 MOON, Sung Hwan
  • 박순정 PARK, Soon-Jung
  • 고윤영 GO, Yun Young
  • 반기원 BAN, Ki Won
Agents
  • 윤대웅 YOON, Dae Woong
Priority Data
10-2020-008463409.07.2020KR
Publication Language Korean (ko)
Filing Language Korean (KO)
Designated States
Title
(EN) COMPOSITION FOR CARDIOMYOCYTE TOXICITY ASSAY OF CANDIDATE DRUG FOR SARS-COV-2 VIRUS, USING HUMAN PLURIPOTENT STEM CELL-DERIVED CARDIOMYOCYTES, AND CARDIOMYOCYTE TOXICITY ASSAY METHOD USING SAME
(FR) COMPOSITION POUR DOSAGE DE TOXICITÉ DE CARDIOMYOCYTES DE MÉDICAMENT CANDIDAT POUR LE VIRUS SARS-COV-2, UTILISANT DES CARDIOMYOCYTES DÉRIVÉS DE CELLULES SOUCHES PLURIPOTENTES HUMAINES, ET PROCÉDÉ DE DOSAGE DE TOXICITÉ DE CARDIOMYOCYTES L'UTILISANT
(KO) 인간 전분화능줄기세포 유래 심근세포를 이용한 SARS-CoV-2 바이러스 대상 후보 약물의 심근세포 독성 평가용 조성물 및 이를 이용한 심근세포 독성 평가 방법
Abstract
(EN) The present invention relates to a composition for cardiomyocyte toxicity assay of a candidate drug for the SARS-CoV-2 virus, using human pluripotent stem cell-derived cardiomyocytes, and a cardiomyocyte toxicity assay method using same. The composition and the method using same, according to the present invention, enable the accurate assessment of cardiomyocyte toxicity of a drug being assessed, and thus may be usefully employed in discovering a new drug candidate for the COVID-19 disease.
(FR) La présente invention concerne une composition pour le dosage de toxicité des cardiomyocytes de médicament candidat pour le virus du SARS-CoV-2, à l'aide de cardiomyocytes dérivés de cellules souches pluripotentes humaines, et un procédé de dosage de toxicité de cardiomyocytes l'utilisant. La composition et le procédé l'utilisant, selon la présente invention, permettent l'évaluation précise de la toxicité des cardiomyocytes d'un médicament en cours d'évaluation, et peuvent donc être utilement employés dans la découverte d'un nouveau médicament candidat pour la maladie du COVID-19.
(KO) 본 발명은 인간 전분화능줄기세포 유래 심근세포를 이용한 SARS-CoV-2 바이러스 대상 후보 약물의 심근세포 독성 평가용 조성물 및 이를 이용한 심근세포 독성 평가 방법에 관한 것으로, 본 발명에 따른 조성물 및 이를 이용한 방법은 대상 약물의 심근세포 독성을 정확하게 평가하는 것이 가능하여, COVID-19 질환의 신약 후보 물질을 발굴하는데 있어 유용하게 활용될 수 있다.
Latest bibliographic data on file with the International Bureau